|
| |
 |
| CASE REPORT |
|
| Year : 2020 | Volume
: 19
| Issue : 4 | Page : 425-427 |
|
Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient
André Marcondes Braga Ribeiro, Thais Menezes Do Nascimento, Eduardo Nóbrega Pereira Lima
Department of Nuclear Medicine, A. C. Camargo Cancer Center, São Paulo, Brazil
| Date of Submission | 14-Feb-2020 |
| Date of Decision | 06-Mar-2020 |
| Date of Acceptance | 31-Mar-2020 |
| Date of Web Publication | 22-Jul-2020 |
Correspondence Address:
Dr. André Marcondes Braga Ribeiro
Department of Nuclear Medicine, A. C. Camargo Cancer Center, Rua Professor Antônio Prudente, 211, 01509-010, Liberdade, São Paulo-SP
Brazil
  | Check |
DOI: 10.4103/wjnm.WJNM_18_20 
 Abstract | | |
Positron emission tomography/computed tomography (PET/CT) using 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) became an important tool in the prostate cancer (PC) diagnosis. Despite its high sensitivity and specificity, this method may produce false-positive findings, as indicated by previous studies. This case report aims to warn nuclear medicine physicians, oncologists, and urologists about the possibility of false-positive findings using this imaging modality, especially in patients who have already been diagnosed with other malignancies. A 69-year-old man, previously treated for an extrapleural solitary fibrous tumor (ESFT), underwent staging tests after a new diagnosis of high-risk PC. 68Ga-PSMA PET/CT imaging revealed an abnormal uptake in the prostate and in the right humerus. A biopsy was performed, and the pathology showed a lesion consisting of an ESFT metastasis. Diagnostic issues related to 68Ga-PSMA PET/CT imaging should be disseminated to help physicians make appropriate treatment choices for each patient and avoid unnecessary procedures. Keywords: 68Ga-prostate-specific membrane antigen, bone metastasis, extrapleural solitary fibrous tumor, false-positive result, prostate cancer
How to cite this article:
Braga Ribeiro AM, Nascimento TM, Lima EN. Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient. World J Nucl Med 2020;19:425-7 |
How to cite this URL:
Braga Ribeiro AM, Nascimento TM, Lima EN. Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient. World J Nucl Med [serial online] 2020 [cited 2021 Jan 27];19:425-7. Available from: http://www.wjnm.org/text.asp?2020/19/4/425/290370 |
| Introduction | |  |
Prostate cancer (PC) is considered the second most common type of cancer in men worldwide, with an estimated 1,3 million new cases in 2018.[1] Bones are the most common site of distant metastasis in PC and occur in approximately 70%–84% of patients in the advanced stage.[2] Several studies have confirmed the high detection rate and the excellent diagnostic performance of the positron emission tomography–computed tomography (PET-CT) study with 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) in high-risk staging and in the recurrence of PC.[3],[4] An accurate detection of the presence of bone metastases is important throughout the course of PC disease to select an ideal treatment strategy and reduce the potential for its possible complications.[5]
However, despite the high sensitivity and specificity for this pathology, the increase in the uptake of 68Ga-PSMA can also occur in normal structures,[6] benign lesions,[7] and other malignant tumors.[8]
Extrapleural solitary fibrous tumor (ESFT) is a rare mesenchymal neoplasm located in the extremities. Preferably affect patients in the fifth decade and have no gender predilection. The majority is benign and healed by complete excision of the lesion. However, 10%–30% of cases have aggressive biological behavior with late recurrences and/or metastases.[9]
In this case report, we intended to advise oncologists, urologists, and nuclear medicine physicians about the possibility of identifying other pathologies using this modality of diagnostic imaging and thus preventing possible unnecessary treatments from being performed on patients with PC.
| Case Report | | |
A.T.P, male, 69 years old, in June 2018, reported a tumor associated with pain in the soft-tissue region of the left forearm. Imaging examinations and a biopsy of the lesion were performed, and a high-grade malignant ESFT was identified. The patient was then submitted to neoadjuvant chemotherapy associated with local radiotherapy and later to marginal resection of the lesion with free margins in the pathological examination.
Six months later, during routine follow-up with his urologist, the patient presented a prostate-specific antigen value of 9.04 ng/mL. He underwent a multiparametric magnetic resonance imaging of the prostate, which demonstrated a highly suspected peripheral prostatic abnormality for clinically significant neoplasia (Prostate Imaging-Reporting and Data System 4). A biopsy of the prostate was then performed by transrectal ultrasound, and the anatomopathological study was compatible with prostate adenocarcinoma, Gleason 9 (4 + 5) in one fragment in the left apex and in two fragments in the left middle third and Gleason 7 (3 + 4) in a fragment at the apex on the right.
In order to complete the PC staging, a PET/CT using a 68Ga-PSMA study was requested. The study demonstrated multiple focal areas of abnormal uptake in the prostate with standard uptake value maximum (SUVmax) up to 5.0 and also a single diffuse intramedullary lesion in the right humerus with SUVmax = 10.8 [Figure 1],[Figure 2],[Figure 3]. No signs of lesions were identified in the pelvic lymph nodes or in the other bones. | Figure 1: Full-body image in the maximum intensity projection showing the abnormal uptake of 68Ga-labeled prostate-specific membrane antigen in the right humerus (arrow)
Click here to view |
 | Figure 2: Axial slices from positron emission tomography–computed tomography fusion (left) and low-dose computed tomography (right) demonstrating the intramedullary uptake of 68Ga-labeled prostate-specific membrane antigen in the right humerus with a standard uptake value maximum of 10.8
Click here to view |
 | Figure 3: Coronal slices from positron emission tomography–computed tomography fusion (left) and low-dose computed tomography (right) demonstrating the intramedullary uptake of 68Ga-labeled prostate-specific membrane antigen in the right humerus
Click here to view |
By the fact that the bone lesion presents in an uncommon site of PC metastasis, because it does not have common anatomical features of PC, and because the patient had already been treated for a high-grade solitary fibrous tumor (SFT), a biopsy of the humeral lesion was performed to identify its etiology.
Finally, the histopathological and immunohistochemical studies confirmed that the humerus lesion was a metastasis of the SFT and the patient received specific treatment for SFT and specific hormone therapy for PC. The radical prostatectomy was contraindicated, which was the initially planned procedure.
| Discusssion | | |
68Ga-PSMA became an important tool in the diagnosis of patients with PC.[3] Despite the high sensitivity and specificity for this pathology, the increased uptake of this radioindicator can also occur in normal structures,[6] benign lesions,[7] and other malignant tumors.[8]
In this report, we identified, for the first time, during the staging of a high-risk PC, an ESFT metastasis. There are an increasing number of reports on the accumulation of 68Ga-PMSA in malignant lesions in addition to PC,[10] and they have already been described in the literature as an overexpression of PSMA in neovascular endothelium of different types of solid epithelial cancer and different malignant soft-tissue tumors,[8] which may explain the presence of PSMA uptake in ESFT, and represent an important pitfall in the clinical use of this diagnostic modality. This knowledge is highly relevant in the interpretation of these studies in patients with PC, providing an adequate direction for treatment.
The present case demonstrates that, although 68Ga-PSMA can be useful in the diagnosis of PC, it can also present possible false-positive results, especially in patients who have already been diagnosed with other malignancies. Thus, physicians should be aware of this when using this diagnostic modality to decide the best treatment option and avoid unnecessary procedures to the patients.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.  |
| 2. | Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014;74:210-6. |
| 3. | Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 2016;70:926-37. |
| 4. | Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-74. |
| 5. | Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004;94:268-71. |
| 6. | Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017;44:2117-36. |
| 7. | Ribeiro AM, Lima ENP, Rocha MM. Fibrous dysplasia as a possible false-positive finding in 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer. World J Nucl Med 2019;18:409-12. [ PUBMED] [Full text] |
| 8. | Heitkötter B, Trautmann M, Grünewald I, Bögemann M, Rahbar K, Gevensleben H, et al. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget 2017;8:4268-76. |
| 9. | Anders JO, Aurich M, Lang T, Wagner A. Solitary fibrous tumor in the thigh: Review of the literature. J Cancer Res Clin Oncol 2006;132:69-75. |
| 10. | Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018;45:860-77. |
[Figure 1], [Figure 2], [Figure 3]
|
Users Online: 215 
